Drugs.com - Clinical Trials

Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

01 March 2025 -- GSK plc (LSE/NYSE: GSK) today announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus placebo (both with standard of care [SOC]) in adults with...

Mar 3, 2025 - 02:32
 0
Depemokimab Delivers Clinically Meaningful and Statistically Significant Improvements for Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
01 March 2025 -- GSK plc (LSE/NYSE: GSK) today announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus placebo (both with standard of care [SOC]) in adults with...
Read More

Tags:

Previous Article

Hollywood Curls, Updos and Crops Ruled The Oscars 2025 Red Carpet

Next Article

Women Who Built Empires: The Female Entrepreneurs Who Broke Glass Ceilings

Related Posts

BlueRock Therapeutics Receives FDA Fast Track Designation for OpCT-001 for the Treatment of Primary Photoreceptor Diseases

BlueRock Therapeutics Receives FDA Fast Track Designati...

Mar 1, 2025  0

Datopotamab Deruxtecan Granted Priority Review in the US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Datopotamab Deruxtecan Granted Priority Review in the U...

Feb 9, 2025  0

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review

U.S. FDA Accepts Gilead’s New Drug Applications for Twi...

Feb 27, 2025  0